Evidence map›Paper›PMID 36328134›Full record

ReviewBiochemical pharmacology2022

Glycosylation in SARS-CoV-2 variants: A path to infection and recovery.

Arya Aloor, Rajaguru Aradhya, Parvathy Venugopal, Bipin Gopalakrishnan Nair, Renuka Suravajhala

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Binding affinity between coronavirus spike protein and human ACE2 receptor.Computational and structural biotechnology journal · 2024
    Review
  16. Article
  17. Article
  18. Variations inBiomolecules · 2023
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Arya AloorSchool of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India. Electronic address: aryaaloor@am.amrita.edu.
Rajaguru AradhyaSchool of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India. Electronic address: rajagurua@am.amrita.edu.
Parvathy VenugopalSchool of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India. Electronic address: parvathyv@am.amrita.edu.
Bipin Gopalakrishnan NairSchool of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India. Electronic address: bipin@am.amrita.edu.
Renuka SuravajhalaSchool of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Clappana 690525, Kerala, India. Electronic address: renus@am.amrita.edu.
Amrita Vishwa Vidyapeetham · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycan is an essential molecule that controls and drives life in a precise direction. The paucity of research in glycobiology may impede the significance of its role in the pandemic guidelines. The SARS-CoV-2 spike protein is heavily glycosylated, with 22 putative N-glycosylation sites and 17 potential O-glycosylation sites discovered thus far. It is the anchor point to the host cell ACE2 receptor, TMPRSS2, and many other host proteins that can be recognized by their immune system; hence, glycosylation is considered the primary target of vaccine development. Therefore, it is essential to know how this surface glycan plays a role in viral entry, infection, transmission, antigen, antibody responses, and disease progression. Although the vaccines are developed and applied against COVID-19, the proficiency of the immunizations is not accomplished with the current mutant variations. The role of glycosylation in SARS-CoV-2 and its receptor ACE2 with respect to other putative cell glycan receptors and the significance of glycan in host cell immunity in COVID-19 are discussed in this paper. Hence, the molecular signature of the glycan in the coronavirus infection can be incorporated into the mainstream therapeutic process.

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2GlycosylationHumansPolysaccharidesSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2PolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2GlycobiologyGlycosylationImmunityVaccine development

Identifiers

PMID36328134
PMCPMC9621623
OpenAlexW4307909012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.